Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Conference Correspondent
ASCO 2015
ASCO 2015 Highlights
Preliminary Evidence for Identifying Patterns of Organ Damage in Advanced Systemic Mastocytosis Subtypes
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
Criteria to assess presenting patterns of organ damage have not been extensively evaluated. Preliminary evidence suggests identifying these patterns could be useful in profiling organ dysfunction in avapritinib clinical trials.
Read Article
Cladribine as First-Line Therapy for Indolent and Advanced Systemic Mastocytosis
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
Cladribine has long been established as an efficient therapy in systemic mastocytosis and remains a valuable treatment option even as new therapies emerge.
Read Article
Genetic Testing for Hereditary Alpha-Tryptasemia in Patients Presenting with Mast-Cell Mediator Symptoms in the Absence of Symptoms of Mastocytosis
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
Hereditary alpha-tryptasemia may promote development of systemic mastocytosis. Screening for variations in copy number of the alpha tryptase gene may provide early evidence for diagnosis of mastocytosis.
Read Article
Assessing the Potential Role of Anti-CD117 CAR T-Cells for Targeted Therapy in Advanced Systemic Mastocytosis
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
CAR T-cell immunotherapy is highly efficient because of its ability to target specific tumor antigens. Preliminary evidence suggests that CAR T-cells directed against CD117, the KIT receptor, may emerge as a therapeutic option for advanced systemic mastocytosis.
Read Article
Whole Genome Sequencing Detects Chromosomal Aberrations Associated with Systemic Mastocytosis
ASH 2021 Systemic Mastocytosis Wrap-Up
Conference Correspondent
Cytogenetic aberrations are rarely found by cytogenetics in systemic mastocytosis but are associated with advanced disease. Whole genome sequencing detects both chromosomal aberrations and non-
KIT
gene mutations and can be used as an alternative to cytogenetics for assessing disease risk.
Read Article
Navigation Is About Value
By
Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN
Videos
Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators (AONN+), said she attended the AVBCC Summit because oncology nurse and patient navigation is "all about value" across the cancer care continuum.
Read Article
Navigators Need a Place at the Table
By
Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN
Videos
We are making progress, but oncology nurse navigators need to have a louder voice in these meetings with stakeholders because, as patient advocates, they are often the keepers of patient experience, said Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators (AONN+).
Read Article
Bringing the Patient Voice to Stakeholders
By
Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN
Videos
Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators (AONN+), said navigators have "boots on the ground" experiences with patients with cancer, their families, and their caregivers, and oncology navigators are the professionals best suited to deliver these voices to the stakeholders who need to hear them.
Read Article
A Navigator for Every Patient
By
Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN
Videos
Every patient with cancer should have a navigator, said Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators (AONN+), and she would like to see AVBCC take a role in realizing this vision.
Read Article
Navigators Have Lessons to Share
By
Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN
Videos
Sharon Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators (AONN+), would like to see everyone with an interest in patient care come to the next AVBCC Summit and learn from navigators how to sustain navigation programs and to learn more about financial navigation.
Read Article
Page 31 of 330
28
29
30
31
32
33
34
Top Trending Articles
1.
FDA Approves Acalabrutinib and Venetoclax Combination for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2.
FDA Launches Unified Adverse Event Monitoring System to Enhance Transparency and Efficiency
3.
Gaps in Biomarker Testing and Targeted Therapy for Gastric Cancer
Ashley Gamble, PhD
,
John Perez, MBA, MSDS
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma